MedTrace Logo

Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

NCT05172700 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2024-12-18

No results posted yet for this study

Summary

This is an expanded access program for eligible participants with a previously treated B-cell cancer who are ineligible for an ongoing pirtobrutinib clinical trial.

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Conditions

  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Lymphocytic, Small
  • Lymphoma, Mantle-Cell
  • Waldenstrom Macroglobulinemia
  • Ritcher's Transformation, Syndrome

Interventions

DRUG

Pirtobrutinib

Administered orally.

Sponsors & Collaborators

  • Loxo Oncology, Inc.

    lead INDUSTRY

Principal Investigators

  • Contact Lilly at 1-800-LillyRx (1-800-545-5979) · Eli Lilly and Company

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05172700 on ClinicalTrials.gov